Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 20/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 17/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 14/20 | 0.67 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.56 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.56 |
| ▸ | TACR1 | P25103 | 2/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.56 |
| ▸ | HRH1 | P35367 | 2/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL228936 | 1.00 | CHRM3 (0.67) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL231048 | 0.85 | CHRM3 (0.66) | CHRM3CHRM2CHRM1 | |
| SCHEMBL231049 | 0.85 | CHRM3 (0.66) | CHRM3CHRM2CHRM1 | |
| SCHEMBL880916 | 0.84 | CHRM3 (0.68) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL231023 | 0.83 | CHRM3 (0.58) | CHRM3CHRM2CHRM1 | |
| SCHEMBL231024 | 0.83 | CHRM3 (0.58) | CHRM3CHRM2CHRM1 | |
| SCHEMBL231036 | 0.82 | CHRM3 (0.63) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL231037 | 0.82 | CHRM3 (0.63) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL2073896 | 0.78 | CHRM3 (0.77) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL72306 | 0.78 | CHRM3 (0.77) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440690-B2 | Quinuclidine carbonate salts and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-05-14 | — | — | US | disclosed |
| US-8440690-B2 | Quinuclidine carbonate salts and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-05-14 | — | — | US | disclosed |
| US-8404712-B2 | Quinuclidine carbonate salts and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-03-26 | — | — | US | disclosed |
| US-8404712-B2 | Quinuclidine carbonate salts and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-03-26 | — | — | US | disclosed |
| EP-2313404-B1 | QUINUCLIDINE CARBONATE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMA SPA (IT) | 2012-03-28 | — | — | EP | disclosed |
| EP-2313404-B1 | QUINUCLIDINE CARBONATE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMA SPA (IT) | 2012-03-28 | — | — | EP | disclosed |
| US-20120004258-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-01-05 | — | — | US | disclosed |
| US-20120004258-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-01-05 | — | — | US | disclosed |
| US-20110319444-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-12-29 | — | — | US | disclosed |
| US-20110319444-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-12-29 | — | — | US | disclosed |
| US-8039483-B2 | Quinuclidine carbonate salts and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-10-18 | — | — | US | disclosed |
| US-8039483-B2 | Quinuclidine carbonate salts and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-10-18 | — | — | US | disclosed |
| EP-2313404-A1 | QUINUCLIDINE CARBONATE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.p.A. (IT) | 2011-04-27 | — | — | EP | disclosed |
| EP-2154136-A1 | Quinuclidine carbonate derivatives and medicinal compositions thereof | CHIESI FARMACEUTICI S.p.A. (IT) | 2010-02-17 | — | — | EP | disclosed |
| EP-2154136-A1 | Quinuclidine carbonate derivatives and medicinal compositions thereof | CHIESI FARMACEUTICI S.p.A. (IT) | 2010-02-17 | — | — | EP | disclosed |
| US-20100035922-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-02-11 | — | — | US | disclosed |
| WO-2010015324-A1 | QUINUCLIDINE CARBONATE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015324-A1 | QUINUCLIDINE CARBONATE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035922-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035922-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHRM3, CHRM2, CHRM4 | CHRM3 1/4885CHRM2 2/4885CHRM1 4/4885 |
| US-20120004258-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHRM3, CHRM2, CHRM4 | CHRM3 1/4885CHRM2 2/4885CHRM1 4/4885 |
| US-20110319444-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHRM3, CHRM2, CHRM4 | CHRM3 1/4885CHRM2 2/4885CHRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.